Loading stock data…
enGene Therapeutics Inc (ENGN)
$1.78+0.03 (+1.71%)
After Hours$1.80+0.02 (+1.12%)· Last close Jun 29
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
enGene Therapeutics Inc. in the Healthcare sector is trading at $1.78 with a market capitalization of $116M. Wall Street consensus targets $3.29 (7 analysts), implying a +84.6% move over the next 12 months. The stock is currently near its 52-week low of $1.40, remaining 74.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +84.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$31.18M↑ | -$39.48M↓ | -$29.95M↓ | -$27.12M↓ | -$26.61M |
| Net Income | -$29.75M↑ | -$37.88M↓ | -$28.99M↓ | -$25.82M↓ | -$24.62M |
Peer Comparison
JNJUNHPFE
Fundamentals
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$115.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.49%
Volume
Today's trading volume
1.03M
Recent News
Neumora depression drug fails; EnGene to cut 50% of staff
Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.
A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations
Why enGene Therapeutics stock is suddenly on investors’ radar enGene Therapeutics (ENGN) is in the spotlight after updated interim data from its Phase 2 LEGEND trial in high risk, BCG unresponsive non muscle invasive bladder cancer, followed by sharp stock moves and fresh legal scrutiny. See our latest analysis for enGene Therapeutics. The latest LEGEND update has flipped sentiment, with the stock’s 1 day share price return of 80.56% decline feeding into a 7 day share price return of 76.34%...
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. On a company call, President and
enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed?
In early May 2026, enGene Therapeutics reported interim Phase 2 LEGEND trial data for its bladder cancer candidate detalimogene voraplasmid, showing a 54% complete response rate but weaker durability than previously hoped, alongside mostly mild and manageable safety findings. The data release has triggered analyst downgrades and shareholder-rights investigations, highlighting how durability of response can be as critical as initial efficacy for late-stage biotech programs. With these...
enGene Therapeutics hit by analyst downgrades as drug data disappoints
Investing.com -- enGene Therapeutics was downgraded by five Wall Street firms after updated interim data from its pivotal LEGEND study of detalimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer showed an unexplained decline in efficacy.